Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 6
1988 6
1989 34
1990 60
1991 104
1992 202
1993 226
1994 216
1995 211
1996 238
1997 188
1998 163
1999 145
2000 149
2001 126
2002 116
2003 123
2004 128
2005 139
2006 147
2007 147
2008 145
2009 159
2010 201
2011 189
2012 176
2013 201
2014 216
2015 214
2016 192
2017 193
2018 197
2019 194
2020 212
2021 210
2022 188
2023 15
Text availability
Article attribute
Article type
Publication date

Search Results

5,317 results
Results by year
Filters applied: . Clear all
Page 1
Ondansetron clinical pharmacokinetics.
Roila F, Del Favero A. Roila F, et al. Clin Pharmacokinet. 1995 Aug;29(2):95-109. doi: 10.2165/00003088-199529020-00004. Clin Pharmacokinet. 1995. PMID: 7586904 Review.
Ondansetron is completely and rapidly absorbed from the gastrointestinal tract after oral administration, and does not accumulate with repeated oral administration. ...Chemotherapeutic agents do not seem to modify the pharmacokinetics of ondansetron. There remains t …
Ondansetron is completely and rapidly absorbed from the gastrointestinal tract after oral administration, and does not accumulate wit …
Safety of ondansetron.
Castle WM, Jukes AJ, Griffiths CJ, Roden SM, Greenstreet YL. Castle WM, et al. Eur J Anaesthesiol Suppl. 1992 Nov;6:63-6. Eur J Anaesthesiol Suppl. 1992. PMID: 1425627 Review.
Ondansetron is a novel 5-HT3 receptor antagonist used for the treatment of cytotoxic-induced emesis and postoperative nausea and vomiting. Safety data from volunteer studies, non-emesis development studies, studies in the treatment of cytotoxic-induced emesis and postopera …
Ondansetron is a novel 5-HT3 receptor antagonist used for the treatment of cytotoxic-induced emesis and postoperative nausea and vomi …
Ondansetron.
Thavaraj V, Arya LS. Thavaraj V, et al. Indian Pediatr. 1995 Aug;32(8):898-901. Indian Pediatr. 1995. PMID: 8635834 Review. No abstract available.
The role of ondansetron in the treatment of schizophrenia.
Bennett AC, Vila TM. Bennett AC, et al. Ann Pharmacother. 2010 Jul-Aug;44(7-8):1301-6. doi: 10.1345/aph.1P008. Epub 2010 Jun 1. Ann Pharmacother. 2010. PMID: 20516364 Review.
Ondansetron daily doses ranged from 4 to 16 mg, with doses administered once or twice daily. ...In all studies, ondansetron was well tolerated, with no severe adverse reactions reported. ...
Ondansetron daily doses ranged from 4 to 16 mg, with doses administered once or twice daily. ...In all studies, ondansetron wa …
Association between early ondansetron administration and in-hospital mortality in critically ill patients: analysis of the MIMIC-IV database.
Fang Y, Xiong C, Wang X. Fang Y, et al. J Transl Med. 2022 May 14;20(1):223. doi: 10.1186/s12967-022-03401-y. J Transl Med. 2022. PMID: 35568908 Free PMC article.
BACKGROUND: While ondansetron (OND) is widespread availability, the contribution of OND to improve patient outcomes among intensive care unit (ICU) patients has not been examined. ...
BACKGROUND: While ondansetron (OND) is widespread availability, the contribution of OND to improve patient outcomes among intensive c …
Pharmacology of ondansetron.
Naylor RJ, Rudd JA. Naylor RJ, et al. Eur J Anaesthesiol Suppl. 1992 Nov;6:3-10. Eur J Anaesthesiol Suppl. 1992. PMID: 1425623 Review.
Ondansetron is a highly potent and selective antagonist at 5-HT3 receptors. ...The absence of other pharmacological effects of ondansetron ensures an absence of side-effects....
Ondansetron is a highly potent and selective antagonist at 5-HT3 receptors. ...The absence of other pharmacological effects of ond …
Clinical safety of ondansetron.
Bryson JC. Bryson JC. Semin Oncol. 1992 Dec;19(6 Suppl 15):26-32. Semin Oncol. 1992. PMID: 1485179 Review.
The safety of intravenous (IV) and oral ondansetron has been evaluated in over 7,000 cancer patients in world-wide clinical trials. ...In addition, ondansetron is well tolerated when administered as a single 32-mg infusion over 15 minutes....
The safety of intravenous (IV) and oral ondansetron has been evaluated in over 7,000 cancer patients in world-wide clinical trials. . …
Ondansetron: a review of its use as an antiemetic in children.
Culy CR, Bhana N, Plosker GL. Culy CR, et al. Paediatr Drugs. 2001;3(6):441-79. doi: 10.2165/00128072-200103060-00007. Paediatr Drugs. 2001. PMID: 11437189 Review.
Ondansetron combined with dexamethasone was significantly more effective than ondansetron or dexamethasone alone, as was the combination of ondansetron with a propofol-based anaesthetic compared with either agent alone. Ondansetron is generally well to …
Ondansetron combined with dexamethasone was significantly more effective than ondansetron or dexamethasone alone, as was the c …
Efficiency and safety of ondansetron in preventing postanaesthesia shivering.
He K, Zhao H, Zhou HC. He K, et al. Ann R Coll Surg Engl. 2016 Jul;98(6):358-66. doi: 10.1308/rcsann.2016.0152. Epub 2016 May 3. Ann R Coll Surg Engl. 2016. PMID: 27138855 Free PMC article. Review.
There was no significant difference between ondansetron and placebo or pethidine in terms of risk of bradycardia but ondansetron was associated with a lower risk of hypotension (RR: 0.26, 95% CI: 0.08-0.79, p=0.020) than placebo. There was no difference in hypotensi …
There was no significant difference between ondansetron and placebo or pethidine in terms of risk of bradycardia but ondansetron …
5,317 results